336 results about "Signal peptide" patented technology

The invention belongs to the field of skin care products, and particularly relates to an anti-wrinkle and anti-aging composition as well as a preparation method and application thereof, and the anti-wrinkle and anti-aging composition comprises neurotransmitter inhibition peptide, signal peptide, madecassoside, inositol and glycosylglycerol. The neurotransmitter inhibition type peptide is at least three of acetyl hexapeptide-8, arginine / lysine polypeptide, dipeptide diaminobutyrylbenzylamide diacetate and acetyl octapeptide-3, and the signal type peptide is at least two of palmitoyl pentapeptide-4, decapeptide-4 and acetyl tetrapeptide-9. Compared with the prior art, all the components of the anti-wrinkle and anti-aging composition act on different anti-aging pathways and can be matched with one another from multiple aspects of oxidation resistance, inflammation resistance, moisturizing, cell viability enhancement, wrinkle reduction and the like, a more comprehensive and better anti-aging effect is provided, skin aging is comprehensively resisted, the skin is in a more young state, and the anti-wrinkle and anti-aging composition has the advantages that the anti-wrinkle and anti-aging effects are achieved. And the anti-wrinkle and anti-aging composition is small in irritation and good in stability.

The invention discloses a recombinant protein for detecting a para-tumor Yo antibody through a CBA method and application, and belongs to the technical field of biomedical engineering.The amino acid sequence of the recombinant protein sequentially comprises a secretory signal peptide, a CDR2 protein partial sequence, a CDR2L protein partial sequence, a transmembrane region and a fluorescent label, and the secretory signal peptide is human albumin signal peptide ALB; the transmembrane region is a CD8a hinge; and the fluorescent label is mCherry. A novel recombinant protein which can be stably over-expressed on a cell membrane of an eukaryotic cell is constructed by intercepting specific partial sequences of CDR2 protein and CDR2L protein and redesigning and fusing a fluorescent label by using a secretory signal peptide, a transmembrane sequence and a connecting peptide, and the recombinant protein retains respective core antigen regions of the CDR2 protein and the CDR2L protein, so that the specific partial sequences of the CDR2 protein and the CDR2L protein can be stably over-expressed on the cell membrane of the eukaryotic cell. The kit can effectively overcome the defects in the aspects of sensitivity and specificity, and when a CBA method is adopted for detection, the detection rate of the para-tumor Yo antibody can be remarkably increased, and the false positive rate is reduced, so that the requirements of clinical detection are better met.

The invention provides a saccharomyces cerevisiae engineering strain HYB05 capable of releasing astaxanthin in a controllable self-splitting manner. The saccharomyces cerevisiae engineering strain HYB05 is constructed by taking a basic strain for producing astaxanthin as a starting strain, introducing a coding sequence comprising cell wall lyase Lyc, a coding sequence of a signal peptide mutant F8A and a recombinant nucleic acid construct for expressing a regulatory element, and knocking out an SSD1 gene to relieve a translation inhibition effect. The cell wall lyase Lyc is found and disclosed by the inventor for the first time, and the amino acid sequence is shown as SEQ ID NO: 6; the amino acid sequence of the signal peptide mutant F8A is as shown in SEQ ID NO: 8. According to the engineering strain HYB05, by introducing the recombinant nucleic acid construct, the activation of the catalytic activity of cell wall lyase under specific conditions is realized, so that the cell wall of the saccharomyces cerevisiae is broken, and the astaxanthin synthesized by the saccharomyces cerevisiae is released. Compared with the prior art, the astaxanthin is produced through fermentation of the strain, the extraction steps are simplified, extraction of the astaxanthin in the yeast is achieved to the maximum extent, the yield of the astaxanthin is remarkably increased, and the technical effect is remarkable.

The invention provides low-temperature alginate lyase and application thereof, namely alginate lyase with low-temperature catalytic activity, which is separated from marine-derived cold monad bacteria, and the amino acid sequence of the alginate lyase is SEQ ID NO: 1; the amino acid sequence of the alginate lyase after the signal peptide is removed is SEQ ID NO: 3. The algin lyase Alg3889 provided by the invention has the optimal reaction temperature of about 10-16 DEG C, has good temperature stability, and still keeps more than 70% of enzyme activity after being incubated at 0-70 DEG C for 1 hour; the optimum pH value of the strain is 8.0, after the strain is incubated in a buffer system with the pH value of 3.0-10.6 for 12 h, about 90% of the highest enzyme activity can be kept, and the strain has high acid resistance and alkali resistance. The degradation product of the alginate oligosaccharide is alginate oligosaccharide with the polymerization degree of 2-6, and the alginate oligosaccharide has high application value.

The invention discloses a variable region amino acid sequence of a monoclonal antibody of a West Nile virus non-structural protein NS1 and application of the variable region amino acid sequence, and belongs to the technical field of medicines. According to the invention, West Nile virus non-structural protein NS1 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the West Nile virus non-structural protein NS1 are screened from rabbit spleen cells through flow sorting, and a signal peptide and a variable region gene fragment of an antibody are cloned through reverse transcription-polymerase chain reaction; according to the present invention, the non-structural protein NS1 of flaviviridae flaviviridae virus is taken as a template, and is connected with a constant region gene to an expression vector, and after mammalian cell expression and purification, the monoclonal antibody which has high affinity and is not combined with the non-structural protein NS1 of other eight viruses of flaviviridae flaviviridae virus is obtained through enzyme-linked immunosorbent assay; the monoclonal antibody has application value in diagnosis and prevention and treatment of West Nile virus infection.

The invention relates to the technical field of plant genetic engineering, and particularly provides cloning of a GbGELP25D gene of gossypium barbadense and application of the GbGELP25D gene of gossypium barbadense. According to the invention, the GbGELP25D gene with a full length of 1092 bp is cloned from the sea island cotton variety Xinhai No. 7 for the first time, and the gene encodes a secretory lipase protein with a signal peptide and is positioned in an extracellular gap. Through bioinformatics analysis, phylogenetic classification, protein structure modeling and signal peptide function verification, it is clear that the gene belongs to a plant GELP family. Furthermore, a virus-induced gene silencing technology is utilized to prove that the silent GbGELP25D can obviously enhance the resistance of cotton to verticillium wilt, and the mechanism of the silent GbGELP25D is closely related to activation of ethylene synthesis and signal channels and induction of expression of disease-resistant related genes. The resistance gene provided by the invention enriches gene resources of cotton verticillium wilt resistance breeding, and has important theoretical significance and application value.

Use of an effective amount of the bioactive peptide in the preparation of a medicament for the prevention and / or treatment of hypoxic-ischemic encephalopathy in newborns, wherein the amino acid sequence of the bioactive peptide contains KKNRNKLRRQHSY or a functionally equivalent variant thereof. Optionally, the bioactive peptide further comprises a signal peptide at its N-terminus or C-terminus.

The present invention provides ROR1 specific chimeric antigen receptors (CAR) and their therapeutic use. The CAR comprises a signal peptide, a ROR1 antigen binding domain, a hinge, a transmembrane domain, a co-stimulatory domain and an intracellular signaling domain. The modified immune cells endowed with such CARs are suitable for treating malignancies such as cancer, chronic lymphocyte leukemia (CLL), and acute lymphocytic leukemia (ALL).

Polynucleotides with an N-terminal signal sequence encode an amino acid sequence encoding a collagen protein or a bacterial collagen-like protein. Fusion products of collagen-like protein with various N-terminal signal peptides lead to increased production of collagen-like protein and secretion in a fermentative process for secreting bacterial collagen-like proteins in a host.

This invention relates to the fields of bioengineering and fermentation engineering, and discloses a genetically engineered *Streptomyces albopictus* strain that produces high levels of ε-polylysine and its fermentation production process. This genetically engineered strain uses *Streptomyces albopictus* strains acclimated to ε-polylysine tolerance as a chassis, and its genome integrates... ppc and dapf Through expression box, heterogeneous asd Expression cassettes, containing secretory signal peptides lysp Fusion expression cassettes and D404A / K499A point mutations pls Expression cassette. The fermentation process employs a two-stage pH control strategy, maintaining a neutral environment during the cell growth phase and adjusting to an acidic environment during product synthesis. This invention improves ε-polylysine yield through a synergistic strategy of enhancing precursor supply, constructing efflux detoxification channels, and increasing synthase activity; combined with an acidic fermentation process, it effectively inhibits product degradation, yielding a high-molecular-weight and highly uniform target product suitable for industrial production.

This document provides novel recombinant polypeptides comprising an endogenous cell protrusion targeting signal peptide and a payload protein, nucleic acid molecules encoding said recombinant polypeptides, pharmaceutical compositions comprising said nucleic acid molecules, and methods of using the same. In some embodiments, the recombinant polypeptide comprises the formula X1-(Y1)a-Z1, wherein X1 is an endogenous signal peptide, Y1 is a peptide linker, and Z1 is a payload protein, wherein a is an integer selected from 0 and 1.

The present disclosure provides a P450 cytochrome enzyme for andrographolide synthesis and its application, belonging to the field of bioengineering. The present disclosure uses Saccharomyces cerevisiae CEN.PK2-1D as a host, and implements knockout of ROX1 and GAL80 genes on the genome, and integrative expression of GGPP synthase encoding gene and CPS diterpene synthase encoding gene at ROX1 site; and implements free expression of ApCPR and CYP71A8 and CYP71D10 both with truncated signal peptides, successfully constructing recombinant S. cerevisiae, and achieving de novo synthesis of 3,15,19-Trihydroxy-8(17),13-ent-labdadiene-16-oic acid. Compared with the blank, a response value of a product peak reaches 1.9*106, and this strategy provides necessary reference for analyzing biosynthetic pathway of andrographolide and using metabolic engineering to synthesize andrographolide and related derivatives thereof.

The invention provides an engineered mesenchymal stem cell secreting GLP-1 / GIP dual agonist-Fc fusion protein and application of the engineered mesenchymal stem cell, and belongs to the technical field of biological medicine. The invention provides a GLP-1 / GIP dual agonist-Fc fusion protein. The fusion protein is formed by sequentially connecting four structural functional domains, namely a signal peptide, a human GIP (1-42) active fragment, a human GLP-1 (7-37) A8G mutant and an Fc fragment of human IgG4 through connecting peptides from an N end to a C end. And an engineering MSC cell strain (GE-MSC) which is derived from the iPSC and is used for expressing the GLP-1 / GIP dual agonist functional protein is constructed by adopting a gene editing technology. The invention creates an intelligent living body medicine factory which can be implanted at one time, autonomously target and stably secrete multifunctional therapeutic molecules for a long time, and has a tissue repair capability, so as to overcome multiple limitations of an existing protein medicine on compliance, medicine effect, cost and disease modification capability.

The invention relates to the technical field of preparation of L-tyrosine, and discloses a method for enhancing generation of L-tyrosine in nicotiana benthamiana and application. In order to relieve product negative feedback inhibition of a key enzyme in a production path of L-tyrosine in tobacco and to improve the yield of L-tyrosine in tobacco, DAHPS enzyme derived from microorganisms is subjected to L175Q site mutation and then is connected with a signal peptide AtRs1A; shikimic acid mutase / prebenzoate dehydrogenase TyrAfbr and tyrosine aminotransferase TyrB which are derived from microorganisms are introduced into the tobacco chassis after being connected with the signal peptide Rs1A, the expression has orthogonality, and transient expression is performed in the Bensi tobacco plant chassis by utilizing agrobacterium infection, so that the synthesis capability of L-tyrosine in tobacco chassis cells can be improved; a large amount of L-tyrosine can be directly generated in the tobacco chassis plastid.

The present invention relates to signal peptides, signal peptide-linkers, fusion polypeptides comprising signal peptide-linker, and polynucleotides encoding the signal peptides, signal peptide-linkers, and fusion polypeptides, and to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing the fusion polypeptides, and methods for increasing secretion of a polypeptide of interest.

Disclosed herein is a method for the treatment of Pompe Disease comprising administering a recombinant AAV (rAAV) vector comprising a rAVV genome comprising a heterologous nucleic acid encoding a GAA signal peptide or portion thereof, a heterologous signal peptide, and an acid alpha-glucosidase (GAA) polypeptide, or N-terminal truncation thereof, where the heterologous nucleic acid is operatively linked to a liver-specific promoter, where the nucleic acid encoding GAA polypeptide can be wild type nucleic acid sequence, or modified nucleic acid sequence, or a codon optimized nucleic acid sequence, and can optionally be modified to reduce or completely eliminate CG and CpG dinucleotides and, optionally eliminated alternative reading frames (ARF) content.

The invention discloses a chikungunya virus envelope E2 protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

The invention provides a chimeric antigen receptor for regulating and controlling a signal time sequence and application of the chimeric antigen receptor. The chimeric antigen receptor sequentially comprises a signal peptide, an extracellular domain, a transmembrane domain and an intracellular domain from an N terminal to a C terminal, the extracellular structural domain comprises an antigen recognition region and a hinge region; the intracellular domain comprises a costimulatory signal transduction region and a CD3 [zeta] intracellular region variant; the CD3 [zeta] intracellular region variant comprises three ITAMs, and the arrangement sequence of the ITAMs is ITAM3-ITAM2-ITAM1 from the N end to the C end. Compared with a conventional chimeric antigen receptor containing a wild CD3 zeta intracellular region, the chimeric antigen receptor provided by the invention can significantly enhance the functional activity of immune cells expressing the chimeric antigen receptor, which is specifically embodied in stronger multiplication capacity and durability, and significantly improves the antigen sensitivity and targeted killing efficacy.

The present invention provides a simple and inexpensive system for regulating signal peptide performance by using a synthetically evolved nucleotide sequence. The invention further relates to an expression vector comprising the nucleotide sequence. Additionally, the present invention relates to host cell comprising the expression vector. Furthermore, the present invention relates to a recombinant protein expressed by the host cell as well as a method for expressing the recombinant protein.

The present application relates to signal peptides for producing Serratia marcescens-derived nuclease and uses thereof. In particular, the present application relates to a polypeptide comprising a signal peptide and a Serratia marcescens-derived nuclease amino acid sequence, a microorganism comprising said polypeptide, and a method of producing Serratia marcescens-derived nuclease, said method comprising the step of culturing said microorganism. The present application can be used for large-scale production of Serratia marcescens-derived nuclease.

The invention discloses a yellow fever virus envelope protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. Yellow fever virus envelope protein E expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the yellow fever virus envelope protein E are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the monoclonal antibody with high neutralizing activity and capable of completely protecting mice from yellow fever virus lethal attack is obtained by using the monoclonal antibody as a template, connecting the monoclonal antibody and the constant region gene to an expression vector, carrying out mammalian cell expression and purification, and carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse virus attack experiment, such that the monoclonal antibody has high neutralizing activity and can completely protect mice from yellow fever virus lethal attack; the monoclonal antibody has application value in prevention and treatment of yellow fever.

The application belongs to the technical field of animal genetic engineering, and particularly discloses a construction method of C1R gene humanized animal cells and animal models and application thereof. The construction method of the C1R gene humanized animal cells comprises the following steps: introducing a human C1R gene into non-human animal cells, so that the human C1R gene is expressed in the non-human animal cells to produce humanized C1R protein, and meanwhile, the expression of an endogenous C1ra gene in the non-human animal cells is reduced or eliminated. The application preferably adopts CRISPR / Cas9 gene editing technology to accurately insert a genomic sequence encoding a human C1R mature protein into a 2nd exon region of a mouse C1ra gene, while retaining a mouse source promoter, a 5' untranslated region (UTR) and a signal peptide sequence. A mouse cell or model capable of specifically interacting with an anti-human C1R antibody is successfully constructed.

The present application relates to a kind of based on logic gate double-target point chimeric antigen receptor modified TIL cell, lentivirus expression vector and application, belong to tumor immunotherapy and gene editing technical field.The TIL cell based on logic gate double-target point chimeric antigen receptor modified in the application, double-target point chimeric antigen receptor includes chimeric antigen receptor EGFR and chimeric antigen receptor GD2;Chimeric antigen receptor EGFR is composed of CD8 alpha signal peptide, anti-EGFR single-chain antibody, CD8 alpha transmembrane region, 4-1BB costimulatory domain and CD3 zeta intracellular signal domain in series;Chimeric antigen receptor GD2 is composed of CD8 alpha signal peptide, anti-GD2 single-chain antibody, CD28 transmembrane region, CD27 costimulatory domain and CD3 zeta intracellular signal domain in series.The present application solves the defects that lentivirus transduction targeting is poor in prior art, CAR signal activation specificity is insufficient, TIL cell is easily exhausted, has the advantages that gene integration is accurate, signal transduction is controllable, in-vivo survival time is long, can be efficiently used for the immunotherapy of double-antigen co-expression solid tumor.

The invention provides a nucleic acid molecule, a mesenchymal stromal cell for promoting angiogenesis and application thereof, and relates to the technical field of biomedicine, the nucleic acid molecule encodes an HGF protein, or encodes a VEGF165 protein and an HGF protein; the first signal peptide is used as a signal peptide of VEGF165 protein, and the second signal peptide is used as a signal peptide of HGF protein. Through a gene modification strategy, the MSC cell containing the nucleic acid molecule stably and efficiently expresses VEGF165 and / or HGF, and the expression quantity of the VEGF165 and / or HGF is obviously higher than that of the MSC without the nucleic acid molecule. The capability of promoting endothelial cell migration is realized; meanwhile, the cells can also remarkably promote proliferation and tube formation of HUVEC cells, and the strong angiogenesis promoting effect of the cells is further proved. The technical problem that in the prior art, nucleic acid molecules for expressing VEGF165 or / HGF cannot be stably and efficiently expressed is solved.

This invention discloses an immune cell that secretes type 2 cytokines under hypoxic conditions and its applications, belonging to the fields of genetic engineering and cell engineering. The invention first constructs a nucleotide fragment encoding hypoxia-induced type 2 cytokines, including a signal peptide gene sequence, a CAR molecule nucleotide sequence targeting CD19 and CD22, and an IL-4 or IL-10 nucleotide sequence containing multiple HRE motifs of a hypoxia-inducible promoter. This nucleotide fragment is delivered to immune cells for stable expression, yielding an immune cell that secretes type 2 cytokines under hypoxic conditions. This immune cell secretes IL-4 or IL-10 only under hypoxic conditions, thereby leveraging the metabolic reprogramming effect of IL-4 or IL-10 on immune cells to enhance their activity under hypoxic conditions, thus achieving better long-term anti-tumor effects.

This invention discloses a lipophilic yeast strain for synthesizing astaxanthin (Yersinia lipophila). Yarrowia lipolytica This invention relates to an engineered strain, its construction method, and its application. The engineered strain is a *Yersinia lipolytica* strain carrying CrtZ and CrtW. The invention utilizes genetic engineering methods to introduce a *Yersinia lipolytica* strain derived from *Rhodochophora* into a β-carotene-producing strain via genetic engineering. Haematococcus Pluvialis The β-carotene hydroxylase encoding gene (HpCrtZ) originates from the genus Paracoccus ( Paracoccus sp. The gene encoding β-carotene ketolase (PsCrtW) and the gene derived from Saccharomyces cerevisiae (Saccharomyces cerevisiae) Saccharomyces cerevisiae The method involves obtaining a genetically engineered *Yersinia lipolytica* strain that produces astaxanthin by constructing a fusion enzyme complex and fusing it with peroxisomes, endoplasmic reticulum, and lipid droplet-targeting signal peptides to obtain a *Yersinia lipolytica* strain with higher astaxanthin yield. The astaxanthin-producing genetically engineered strain constructed in this invention achieved an astaxanthin yield of 1.43 g / L in a 5 L bioreactor after pH control and continuous feeding optimization.

Provided herein are engineered fusion proteins comprising ApoM (e.g., human or murine ApoM) fused to a constant region (Fc) of a immunoglobulin G (IgG, e.g., human IgG or murine IgG). In some embodiments, the ApoM-Fc fusion protein further comprises a signal peptide (e.g., IL-2 signal peptide) fused to the ApoM, allowing the fusion protein to be secreted once expressed recombinantly. Methods of using the ApoM-Fc fusion protein or the sponge variants in the treatment of various diseases or disorders are provided.

The invention provides a gene expression cassette for improving CsCE expression quantity and application. The gene expression cassette provided by the invention comprises a regulatory element and a target gene, the regulatory element comprises at least one of a coding sequence of dtRNA, a coding sequence of a signal peptide and a coding sequence of a fusion tag, and the target gene comprises a coding sequence of CsCE enzyme. Wherein the dtRNA contributes to keeping the structural stability when the CsCE enzyme is transcribed into mRNA, the signal peptide can promote the secretion of the CsCE enzyme, and the fusion tag can assist the correct folding of the CsCE enzyme, so that the expression of the CsCE enzyme can be synergistically regulated under the three-tube alignment of a DNA transcriptional mRNA layer, a protein secretion layer and a protein folding layer, the expression quantity of the CsCE enzyme can be effectively up-regulated, and the expression quantity of the CsCE enzyme can be effectively up-regulated. Therefore, the volume enzyme activity of the CsCE enzyme is improved, and the CsCE enzyme with higher volume enzyme activity can catalyze lactose to be converted into lactulose in the preparation of lactulose, so that the preparation yield of lactulose is improved.

The present invention relates to a plasmid that encodes a fusion protein comprising a signal peptide and the extracellular domain of the B-cell activating factor receptor (BAFF-R), and optionally, a fragment of the constant region (Fc) of an immunoglobulin. The invention also relates to compositions comprising said plasmid, and to the use of same in the treatment and / or prevention of inflammatory diseases in fish, more preferably in salmonids.

The invention provides a signal peptide category and cleavage site prediction method and system based on multi-modal characteristics, and belongs to the technical field of biological information analysis. The method comprises the following steps: acquiring an amino acid sequence of a signal peptide sample, and acquiring three-dimensional structure data of the signal peptide by utilizing a protein structure prediction model; obtaining sequence modal input data of the amino acid sequence of the signal peptide, and constructing a structural diagram to obtain structural modal input data; inputting the sequence modal input data into a sequence encoder and a protein language model, and extracting sequence features; inputting the structural modal input data into a structural encoder, and extracting structural features through graph convolution operation; carrying out fusion processing on the sequence features and the structural features to obtain multi-modal feature representation; and outputting a category prediction result and a cleavage site prediction result of the signal peptide through a prediction module. According to the invention, through fusion of the sequence and the structure information, the accuracy of signal peptide prediction and the recognition capability of minority class samples are improved.